Xenon Pharmaceuticals (XENE) Operating Expenses (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Operating Expenses data on file, last reported at $112.3 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 28555.1% year-over-year to $112.3 million in Q1 2026; TTM through Mar 2026 was -$64.8 million, a 68.45% increase from a year earlier, with the FY2025 full-year figure at -$332000.0, up 89.02% from the prior year.
• Operating Expenses for Q1 2026 stood at $112.3 million, up from -$271.1 million in the prior quarter.
• Over the last five years, Operating Expenses for XENE reached as high as $112.3 million in Q1 2026 and fell as low as -$271.1 million in Q4 2025.
• Historically, Operating Expenses has averaged $8.3 million across 5 years, with a median of $38.3 million in 2022.
• Across the five-year window, Operating Expenses sank 577.55% in 2025 and surged 28555.1% in 2026, its largest moves.
• Year by year, Operating Expenses stood at $43.3 million in 2022, then advanced by 23.92% to $53.7 million in 2023, then plunged by 481.5% to -$204.8 million in 2024, then slumped by 32.36% to -$271.1 million in 2025, then soared by 141.43% to $112.3 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $112.3 million in Q1 2026, -$271.1 million in Q4 2025, and $96.3 million in Q3 2025.